Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study
出版年份 2019 全文链接
标题
Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study
作者
关键词
-
出版物
LEUKEMIA
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2019-09-13
DOI
10.1038/s41375-019-0545-2
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial
- (2019) Yuankai Shi et al. Lancet Haematology
- Prolonged remissions after anti-PD-1 discontinuation in patients with Hodgkin lymphoma
- (2018) Guillaume Manson et al. BLOOD
- Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma
- (2018) Margaretha G.M. Roemer et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial
- (2018) Philippe Armand et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma
- (2017) Robert Chen et al. JOURNAL OF CLINICAL ONCOLOGY
- Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy
- (2017) Diego Chowell et al. SCIENCE
- Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma
- (2016) R. Chen et al. BLOOD
- Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy
- (2016) Bruce D. Cheson et al. BLOOD
- Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure
- (2016) Philippe Armand et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome
- (2016) Margaretha G.M. Roemer et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial
- (2016) Anas Younes et al. LANCET ONCOLOGY
- Classical Hodgkin Lymphoma with Reduced 2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status
- (2016) M. G. M. Roemer et al. Cancer Immunology Research
- The new therapeutical scenario of Hodgkin lymphoma
- (2015) A. Stathis et al. ANNALS OF ONCOLOGY
- FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis
- (2015) Rony Dahan et al. CANCER CELL
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
- (2015) Stephen M. Ansell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma
- (2014) A. K. Gopal et al. BLOOD
- Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification
- (2014) Bruce D. Cheson et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies
- (2013) B. J. Chen et al. CLINICAL CANCER RESEARCH
- Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study
- (2013) Anas Younes et al. LANCET ONCOLOGY
- Distribution of Lymphoid Neoplasms in China
- (2012) Jian Sun et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Hodgkin lymphoma: 2012 update on diagnosis, risk-stratification, and management
- (2012) Stephen M. Ansell AMERICAN JOURNAL OF HEMATOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More